239825 InSolution™ CXCR4 Antagonist I, AMD3100 - CAS 155148-31-5 - Calbiochem

239825
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité

      Aperçu

      Replacement Information

      Prix & Disponibilité

      Référence DisponibilitéConditionnement Qté Prix Quantité
      239825-15MG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Flacon en verre 15 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewA symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4 (IC50 = 108 and 245 nM using rat and human CXCR4, respectively) and inhibits SDF1-induced Ca2+ flux (by 100% at 100 ng/ml in SUP-T1 and THP-1 cultures) as well as CXCR4-, but not CCR5-, mediated HIV infection (IC50 = 200 nM), while enhancing the binding of SDF1 to CXCR7 (by ~60% at 1 mM with CXCR7-expressing HEK293T cells) and SDF1-induced β-arrestin recruitment to CXCR7 (EC50 = 6.48 and 11.8 nM, in the presence and absence of 10 µM AMD3100, respectively). Administration AMD3100 via intravenous infusion is also reported to result in hematopoietic stem cell mobilization in humans, dogs, and mice in vivo. Exhibits no inhibitory effects against chemokine-induced signaling via CXCR1/2/3 or CCR1/2/3/4/5/6/7/8/9.
          Catalogue Number239825
          Brand Family Calbiochem®
          Synonyms1,1ʹ(1,4-Phenylenebis(methylene))-bis-1,4,8,11-tetraazacyclotetradecane, 8HCl, 4H₂O, 1,4-bis((1,4,8,11-Tetraazacyclotetradecan-1-yl)methyl)benzene, 8HCl, 4H₂O
          References
          ReferencesKalatskaya, I., et al. 2009. Mol. Pharmacol. 77, 1240.
          Pitchford, S.C., et al. 2009. Cell Stem Cell 4, 62.
          De Clercq, E. 2009. Biochem. Pharmacol. 77, 1655.
          Thoma, G., et al. 2008. J. Med. Chem. 51, 7915.
          De Clercq, E. 2000. Mol. Pharmacol. 57, 833.
          Product Information
          CAS number155148-31-5
          FormLiquid
          FormulationA 50 mM (15 mg/308 µL) solution of CXCR4 Antagonist I, AMD3100 (Cat. No. 239820) in H₂O.
          Hill FormulaC₂₈H₅₄N₈ • 8HCl • 4H₂O
          Chemical formulaC₂₈H₅₄N₈ • 8HCl • 4H₂O
          ReversibleY
          Structure formula ImageStructure formula Image
          Quality LevelMQ100
          Applications
          Biological Information
          Primary TargetCXCR4
          Purity≥98% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage ≤ -70°C
          Protect from Light Protect from light
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 1 year at -70°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          InSolution™ CXCR4 Antagonist I, AMD3100 - CAS 155148-31-5 - Calbiochem FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          InSolution™ CXCR4 Antagonist I, AMD3100 - CAS 155148-31-5 - Calbiochem Certificats d'analyse

          TitreNuméro de lot
          239825

          Références bibliographiques

          Aperçu de la référence bibliographique
          Kalatskaya, I., et al. 2009. Mol. Pharmacol. 77, 1240.
          Pitchford, S.C., et al. 2009. Cell Stem Cell 4, 62.
          De Clercq, E. 2009. Biochem. Pharmacol. 77, 1655.
          Thoma, G., et al. 2008. J. Med. Chem. 51, 7915.
          De Clercq, E. 2000. Mol. Pharmacol. 57, 833.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision19-March-2013 JSW
          Synonyms1,1ʹ(1,4-Phenylenebis(methylene))-bis-1,4,8,11-tetraazacyclotetradecane, 8HCl, 4H₂O, 1,4-bis((1,4,8,11-Tetraazacyclotetradecan-1-yl)methyl)benzene, 8HCl, 4H₂O
          DescriptionA symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4 (IC50 = 108 and 245 nM using rat and human CXCR4, respectively) and inhibits SDF1-induced Ca2+ flux (by 100% at 100 ng/ml in SUP-T1 and THP-1 cultures) as well as CXCR4-, but not CCR5-, mediated HIV infection (IC50 = 200 nM), while enhancing the binding of SDF1 to CXCR7 (by ~60% at 1 mM with CXCR7-expressing HEK293T cells) and SDF1-induced β-arrestin recruitment to CXCR7 (EC50 = 6.48 and 11.8 nM, in the presence and absence of 10 µM AMD3100, respectively). Administration AMD3100 via intravenous infusion is also reported to result in hematopoietic stem cell mobilization in humans, dogs, and mice in vivo. Exhibits no inhibitory effects against chemokine-induced signaling via CXCR1/2/3 or CCR1/2/3/4/5/6/7/8/9.
          FormLiquid
          FormulationA 50 mM (15 mg/308 µL) solution of CXCR4 Antagonist I, AMD3100 (Cat. No. 239820) in H₂O.
          Intert gas (Yes/No) Packaged under inert gas
          CAS number155148-31-5
          Chemical formulaC₂₈H₅₄N₈ • 8HCl • 4H₂O
          Structure formulaStructure formula
          Purity≥98% by HPLC
          Storage ≤ -70°C
          Protect from light
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 1 year at -70°C.
          Toxicity Standard Handling
          ReferencesKalatskaya, I., et al. 2009. Mol. Pharmacol. 77, 1240.
          Pitchford, S.C., et al. 2009. Cell Stem Cell 4, 62.
          De Clercq, E. 2009. Biochem. Pharmacol. 77, 1655.
          Thoma, G., et al. 2008. J. Med. Chem. 51, 7915.
          De Clercq, E. 2000. Mol. Pharmacol. 57, 833.